Table of Contents
Published: June 3, 2026
Read Time: 7.5 Mins
Total Views: 116
Pfizer and Valneva recently announced phase 3 results for a new Lyme disease vaccine candidate, PF-07307405, with efficacy of roughly 73 percent against confirmed Lyme infection. For a disease that affects approximately 476,000 Americans every year and that can produce arthritis, cardiac complications, and neurologic disease when untreated, this is the kind of result that should be greeted with something close to celebration. It is being greeted instead with the kind of careful, qualified hope that reflects what the United States has learned, the hard way, about what happens when a useful vaccine arrives in a hostile political environment.
How the new vaccine works
The mechanism by which PF-07307405 protects against Lyme disease is unusual enough to be worth understanding on its own merits. Most vaccines work by training the immune system to recognize a pathogen so that, when the pathogen later enters the body, the immune response can neutralize it before it establishes infection. The Lyme vaccine takes a different approach. It generates antibodies in the bloodstream that a tick ingests when it bites, and those antibodies disable the Borrelia bacteria inside the tick itself, before the bacteria can be transmitted into the human host. The protection happens, in effect, inside the tick rather than inside the person. It is an elegant design, and it represents a meaningful piece of biological engineering applied to one of the most common vector-borne diseases in North America.
In the VALOR trial, Vaccine Against Lyme for Outdoor Recreationists, the vaccine was 73 percent effective at preventing confirmed Lyme disease 28 days after a fourth dose, and roughly 75 percent effective one day after the fourth dose. These are strong numbers for a vaccine against a bacterial infection transmitted by an arthropod vector, and they are consistent with what would be needed for the vaccine to make a substantial dent in national disease burden.
The problem hidden in the trial results
The numbers come with a complication that matters for regulatory approval. Fewer Lyme cases occurred during the trial than the statistical plan had anticipated, which means the primary endpoint was not technically met, even though the secondary analysis supported efficacy. This is a familiar problem in vaccine trials against diseases whose incidence varies year to year and region to region. The fundamental signal is real and substantial. The way the trial was designed did not produce enough events to reach the statistical threshold the protocol had specified in advance. Pfizer says it will submit for regulatory approval, and the FDA will have to decide how to weigh a strong but technically-not-quite-significant primary result against secondary analyses that point in the same direction.
A four-dose schedule is the second complication, and as a physician and as someone who has led large-scale vaccine programs, I find this one more worrying than the statistical question. Three shots in the first year, followed by a booster before the next tick season, asks more of patients than almost any other adult vaccine on the U.S. schedule. Even when adults intend to complete a multi-dose vaccine series, real-world completion rates fall off steeply with each additional dose. The vaccine that protects 73 percent of people who finish the series will protect substantially fewer in actual practice, because actual practice will involve a meaningful percentage of people who get one or two doses and then never come back.
What happened the last time we had a Lyme vaccine
The story most people do not know is that the United States has been here before. In 1998, the Food and Drug Administration approved a Lyme vaccine called LYMErix, which was about 76 percent effective. The scientific data for vaccine effectiveness was strong. Demand for the vaccine nonetheless collapsed within a few years because some people who had received it began reporting arthritis-like symptoms, and a class-action lawsuit followed. When the data was examined carefully, the rate of arthritis-like symptoms in vaccine recipients turned out to be similar to the rate in the general population, and the symptoms did not correlate with the second or third dose in the pattern you would expect from a true immune-driven side effect. The vaccine was almost certainly not causing the symptoms attributed to it. The perception that it was causing them was sufficient to destroy the market. GlaxoSmithKline pulled LYMErix from the market in 2002, and the country has gone without a Lyme vaccine for more than two decades.
The LYMErix story is worth dwelling on because it illustrates a recurring failure mode in American vaccine policy. A useful vaccine arrives, public attention focuses on a rare or perceived adverse event, the litigation environment turns hostile, the manufacturer makes a commercial decision to withdraw the product, and the underlying public health problem returns to its pre-vaccine baseline while the data quietly demonstrates that the vaccine was working. The cost of that failure has been borne not by the lawyers or the manufacturer but by every person who has developed Lyme disease in the intervening twenty-plus years, including the substantial subset who will go on to develop chronic complications.
The political question that will determine what happens next
The technical questions about PF-07307405, the four-dose schedule, the primary endpoint, the long-term durability of protection, are real and will be worked through over time. The political question is harder. The current federal environment is the most hostile to vaccines that the United States has seen in modern history. The FDA has signaled a willingness to second-guess the methods that vaccine scientists have used for decades. The CDC, traditionally the agency that promotes approved vaccines, has been reorganized in ways that make its advocacy role uncertain. The broader political climate has rewarded skepticism toward vaccines in general, regardless of the underlying evidence. This is the same dynamic I have written about in the context of the CDC’s handling of vaccine data, where institutional choices about which evidence to publish and which to suppress have started to shape the public conversation in ways that the underlying science cannot easily correct.
The questions that will determine whether PF-07307405 actually protects Americans from Lyme disease are not primarily scientific. They are whether the FDA will approve a vaccine whose primary endpoint missed by a narrow margin, whether the CDC will recommend it if it is approved, whether physicians will offer it to their patients, and whether patients will accept it given the current discourse about vaccines. None of these questions is being answered in a vacuum. Each will be answered against the backdrop of a political environment that has made it harder for every vaccine to reach the people who need it.
The cost of repeating LYMErix
The Northeast and Midwest are already reporting three-fold increases in tick-bite emergency department visits over March levels, with the Northeast approaching 50 visits per 100,000. Tick populations are expanding northward as warming temperatures allow them to survive in regions that were previously too cold, and tick activity is extending into months that used to be safe. This is the trajectory against which any decision about the Lyme vaccine will play out. The disease is becoming more common, the geographic range of the vector is expanding, and the human cost of going without a vaccine is rising every year.
If the United States walks away from PF-07307405 the way it walked away from LYMErix, the consequences will not be theoretical. They will show up over the next two decades in arthritis cases, in cardiac complications, in the patients with post-treatment Lyme disease syndrome who will go on suffering because the vaccine that could have prevented their infection was never deployed. The history of the previous Lyme vaccine is a warning. Whether the country has learned anything from that warning will become clear soon enough.
